BioVersys AG (SWX:BIOV)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
28.20
+5.10 (22.08%)
At close: Mar 12, 2026
Market Cap135.09M -35.5%
Revenue (ttm)1.31M +6.5%
Net Income-19.36M
EPS-4.34
Shares Out5.85M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume19,767
Average Volume2,472
Open23.10
Previous Close23.10
Day's Range22.90 - 28.50
52-Week Range21.20 - 36.60
Betan/a
RSI67.62
Earnings DateMar 18, 2026

About BioVersys AG

BioVersys AG, a clinical stage biopharmaceutical company, focuses on identification, development, and commercialization of novel antibacterial products for serious life-threatening infections caused by multi-drug-resistant bacteria. It develops BV100 that is in Phase 3 clinical trial for carbapenem resistant Acinetobacter baumannii lung and blood stream infections; and in Phase 1 trial in patients with hepatic impairment and a bronchoalveolar lavage (BAL). The company is also developing Alpibectir that is in Phase 2a clinical trial for the trea... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 29
Stock Exchange SIX Swiss Exchange
Ticker Symbol BIOV
Full Company Profile

Financial Performance

Financial Statements